An announcement from Cingulate Inc ( (CING) ) is now available.
Cingulate Inc. has reinstated the pre-cut salaries of its top executives and continues to achieve cost savings following workforce reductions. The company has also successfully raised over $10 million in additional capital and initiated the final FDA-required study for its lead ADHD treatment, CTx-301, with results expected by the end of 2024. This progress has enabled Cingulate to meet Nasdaq listing requirements, marking a significant stride towards the anticipated mid-2025 NDA submission for CTx-1301.
For detailed information about CING stock, go to TipRanks’ Stock Analysis page.
